Second Annual Meeting of
August 15-18, 2003, Hyatt Regency, San Francisco, CA USA
Educational Objectives & Continuing Medical Education
Accreditation Statement:This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of the International Society for Magnetic Resonance in Medicine (ISMRM) and the Society for Molecular Imaging. The ISMRM is accredited by the ACCME to provide continuing medical education for physicians.
Designation Statement:
The International Society for Magnetic Resonance in Medicine designates this continuing medical
education activity for up to 25 hours in Category 1 of the Physician's Recognition Award of
the American Medical Association. Each physician should claim only those hours of credit
actually spent in the educational activity.
Disclosure:
The Society for Molecular Imaging and the International Society for Magnetic Resonance in
Medicine have a policy regarding disclosure of financial relationships. It requires speakers
and poster presenters to disclose whether or not they have financial interests or affiliations
with organizations with a direct and substantial interest in the subject matter of their
presentations. This information will be provided with each published abstract and as an
addendum to the speaker listing as a matter of information for the audience.
Who Should Attend?
The intended audience consists of researchers, clinical practitioners, trainees and other
professionals in radiology, neuroradiology, neurology, oncology, nuclear medicine, cardiology,
medical physics, cell biology, molecular biology, genetics, immunology and medical imaging
equipment companies.
Upon completion of this conference participants should be able to:
- Explain methods of target identification and probe development for disease targets.
- Describe current state-of-the-art of cancer detection and outcome measures.
- Compare data from various molecular imaging modalities that demonstrate significant advantages of different imaging strategies.
- Evaluate the potential of new imaging methods to detect disease early in its course and recognize when there is the potential for improved outcome.
- Describe the new imaging paradigms in drug discovery and development.
- Recommend imaging and therapy combinations.
- Appraise Imaging in the development of cellular and gene therapy.
